Royalty Pharma (RPRX) Net Income Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Net Income Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 1,228.66% |
| 10 | Royalty Pharma | 25.77 Bn | 25.16 Bn | - | 7.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.79% |
| Dec 31, 2025 | 6.45% |
| Sep 30, 2025 | -44.91% |
| Jun 30, 2025 | -53.37% |
| Mar 31, 2025 | 10,266.93% |
| Dec 31, 2024 | -53.41% |
| Sep 30, 2024 | 560.53% |
| Jun 30, 2024 | -44.67% |
| Mar 31, 2024 | -100.84% |
| Dec 31, 2023 | 217.63% |
| Sep 30, 2023 | -44.61% |
| Jun 30, 2023 | -28.53% |
| Mar 31, 2023 | 297.47% |
| Dec 31, 2022 | -1,236.61% |
| Sep 30, 2022 | -0.62% |
| Jun 30, 2022 | -39.06% |
| Mar 31, 2022 | -19.43% |
| Dec 31, 2021 | -85.36% |
| Sep 30, 2021 | -64.47% |
| Jun 30, 2021 | 34.02% |